Don't worry about the drug industry's profits when considering a waiver on covid-19 intellectual property rights.

Hawksbee, Luke; McKee, Martin; King, Lawrence

Hawksbee, Luke; McKee, Martin; King, Lawrence.

Hawksbee L; Department of Sociology, University of Cambridge, Cambridge, UK lh372@cam.ac.uk.
McKee M; Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
King L; Department of Economics, University of Massachusetts, Amherst, MA, USA.

BMJ ; 376: e067367, 2022 01 31.

Article in English | MEDLINE | ID: covidwho-1662307

Subject(s)

COVID-19 Vaccines/economics; COVID-19/prevention & control; Drug Industry/economics; Intellectual Property; Public Policy/economics; Drug Industry/ethics; Drug Industry/legislation & jurisprudence; Humans; Public Policy/legislation & jurisprudence; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Public Policy / Intellectual Property / Drug Industry / COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: BMJ Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Bmj-2021-067367

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google